首页> 外文期刊>P & T: a peer-reviewed journal for formulary management >Ledipasvir/sofosbuvir (Harvoni): Improving options for hepatitis C virus infection
【24h】

Ledipasvir/sofosbuvir (Harvoni): Improving options for hepatitis C virus infection

机译:Ledipasvir / sofosbuvir(Harvoni):改善丙型肝炎病毒感染的选择

获取原文
获取原文并翻译 | 示例
       

摘要

Hepatitis C is an infectious liver disease caused by the hepatitis C virus (HCV), a single-stranded RNA virus.1 Those infected usually develop acute hepatitis C, which spontaneously clears in 15% to 45% of infected persons. The incubation period for acute hepatitis is anywhere from two weeks to six months, and most patients remain asymptomatic. Early diagnosis of HCV infection is rare, and the disease may go unnoticed until patients have already developed serious liver damage.
机译:丙型肝炎是由丙型肝炎病毒(HCV)(一种单链RNA病毒)引起的传染性肝病。1被感染者通常会发展为急性丙型肝炎,这种感染会自发清除15%至45%的感染者。急性肝炎的潜伏期从两周到六个月不等,大多数患者保持无症状。 HCV感染的早期诊断很少见,直到患者已经出现严重的肝损害,该疾病才可能被忽视。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号